On Monday afternoon, the European Medicines Agency authorized the marketing of the Pfizer-BioNTech vaccine “conditionally,” paving the way for a possible start of vaccinations in Europe before end of the year.
The Amsterdam-based European Medicines Agency (EMA) announced today that it was authorizing the Pfizer-BioNTech vaccine. Europe now joins the U.K., the U.S., Canada, Bahrain, Saudi Arabia, Mexico, Singapore, Israel and Switzerland in the list of countries that have approved its use.
During a press conference, AEM CEO Emer Cooke stated, “I am delighted to announce that the AEM Scientific Committee has met today and supported a conditional marketing authorization in the EU for the vaccine developed by Pfizer and BioNTech.
The European Commission must now approve this decision in order to launch the vaccination campaign throughout the European Union, which has nearly 450 million inhabitants. However, the EMA has set conditions for the administration of the vaccine, including being over 16 years old.
EU commission president Ursula Von der Leyen tweeted “It’s a decisive moment in our efforts to deliver safe & effective vaccines to Europeans! We will act quickly. I await a decision from the European Commission in the evening.”
Last Friday, Monaco's minister of state Pierre Dartout said a national vaccination plan is under development and set to be unveiled at the start of the school year pending this validation from the European Medicines Agency. For this non-mandatory and free vaccination campaign, three groups have been identified as priority: over-75s, over-65s and medical and healthcare staff. The vaccination center will be open at the Espace Léo Ferré in the presence of doctors and pharmacists, with mandatory appointments made at the Covid Center.
Feature image: European Medicines Agency Executive Director Emer Cooke. Photo: EMA/Europe.
Further Details About Holidays in Monaco